Entera Bio Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Entera Bio Ltd., a foreign private issuer, covers the month of October 2021. The report, dated October 28, 2021, consists solely of a press release attached as Exhibit 99.1 and incorporated by reference. The registrant is based in Jerusalem, Israel, and files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a vehicle to distribute a press release and does not contain a financial statement or quantitative financial data within the provided text.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. No comparative financial data or operational metrics are included in the cover document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for specific guidance, outlook, management commentary, risks, contingencies, or unusual items. While the filing incorporates a press release by reference, the content of that release is not included in the provided text, preventing a summary of management's forward-looking statements or risk factors.
Key Facts for Investor Verification
- The filing is a procedural Form 6-K incorporating a press release dated October 28, 2021, as Exhibit 99.1.
- No financial data (revenue, cash, debt) is present in the provided text; investors must review the attached press release for details.
- The document is signed by Spiros Jamas, Sc.D., Chief Executive Officer and Director.
- The filing is incorporated by reference into the company's Form F-3 registration statements (Nos. 333-238988 and 333-239843).